Skip to main content

Table 1 Basic characteristics of patients in the derivation set and validation set

From: Development and validation of a clinical prediction model for detecting coronary heart disease in middle-aged and elderly people: a diagnostic study

Indicators

Derivation set (n = 588)

Validation set (n = 251)

Statistics

P values

Demographics

 Male, N (%)

278 (47.28)

112 (44.62)

0.499a

0.480

 Age, years

60 (56, 67)

62 (56, 69)

-1.552b

0.121

 BMI, kg/m2

25.71 (24.06, 27.84)

25.81 (24.06, 27.85)

0.016b

0.987

Past medical history

 Smoking, N (%)

159 (27.04)

76 (30.28)

0.915a

0.339

 Diabetes, N (%)

250 (42.52)

107 (42.63)

0.001a

0.976

Hypertension, N (%)

357 (60.71)

136 (54.18)

3.096a

0.078

 Heart failure NYHA I-II, N (%)

25 (4.25)

15 (5.98)

1.152a

0.283

 Atrial fibrillation, N (%)

22 (3.74)

8 (3.19)

0.157a

0.692

Prior medication use

 Anti-platelet, N (%)

487 (82.82)

199 (79.28)

1.479a

0.224

 Statins, N (%)

471 (80.10)

187 (74.50)

3.261a

0.071

 ACEI/ARB, N (%)

329 (55.95)

119 (47.41)

5.158a

0.023

 Beta-blockers, N (%)

457 (77.72)

206 (82.07)

2.009a

0.156

 CCB, N (%)

309 (52.55)

121 (48.21)

1.329a

0.249

 Nitrates, N (%)

265 (45.07)

98 (39.04)

2.601a

0.107

Laboratory values

 ALT, IU/L

20 (15, 28)

19 (14, 28)

1.086b

0.278

 AST, IU/L

20 (15, 28)

19 (16, 23)

1.801b

0.072

 Scr, μmol/L

69 (58.3, 79.75)

67.4 (57.45, 79.65)

0.969b

0.333

 Hs-CRP, mg/L

1.41 (0.64, 3.13)

1.55 (0.77, 3.12)

− 1.634b

0.102

 TC, mmol/L

4.02 (3.26, 4.72)

3.95 (3.24, 4.71)

0.674b

0.500

 TG, mmol/L

1.35 (1.04, 1.82)

1.30 (0.99, 1.84)

0.724b

0.469

 LDL-C, mmol/L

2.4 (1.91, 2.97)

2.42 (1.93, 2.95)

0.240b

0.810

 HDL-C, mmol/L

1.1 (0.96, 1.3)

1.13 (0.93, 1.31)

-0.004b

0.997

 HCY, μmol/L

13.37 (11.22, 15.84)

14.18 (10.77, 17.03)

− 1.385b

0.166

 HbA1c, %

6.1 (5.6, 7)

6 (5.6, 6.8)

0.412b

0.681

 NT-proBNP, pg/mL

80 (42, 162)

93.5 (54, 182.5)

− 1.841b

0.066

Arterial stiffness indices

 baPWV, m/s

17.24 (15.24, 19.80)

18.11 (15.69, 19.25)

− 1.878b

0.060

 ABI

1.13 (1.05, 1.22)

1.12 (1.04, 1.22)

0.264b

0.792

Vascular endothelial function test

 FMD, %

7.7 (6.9, 9)

7.55 (6.8, 8.9)

0.861b

0.390

Echocardiographic values

 LAD, mm

37 (34, 40)

37 (34, 40)

− 0.870b

0.384

 LVEF, %

68 (63.5, 71)

68 (64, 71)

− 0.810b

0.418

 LVMI, g/m2

87.8 (75.73, 101.87)

88.28 (74.27, 103.71)

− 0.246b

0.806

  1. Data were expressed as means ± standard deviations or as medians with interquartile ranges or as frequencies and percentages
  2. BMI body mass index, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blockers, ALT alanine aminotransferase, AST aspartate aminotransferase, Scr serum creatinine, Hs-CRP hypersensitive C-reactive protein, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HCY homocysteine, HbA1c hemoglobin A1c, NT-proBNP N-terminal pro-B-type natriuretic peptide, baPWV brachial-ankle pulse wave velocity, ABI ankle-brachial index, FMD brachial artery flow-mediated vasodilatation, LAD left atrium diameter, LVEF left ventricular ejection fraction, LVMI left ventricular mass index. ax2 value, bZ value
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us